A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules ...

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 ...

Explore the implications of GLP-1 drugs in managing India's obesity crisis as experts warn of potential misuse and health ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type ...